Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Status:
Completed
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
Background:
Ependymomas are rare tumors that arise from the ependyma. That is a tissue of the central
nervous system. They can develop in the brain or the spine. They are usually treated with
surgery, radiation, and/or chemotherapy. Researchers want to see if the new drug marizomib
can help people with a certain kind of ependymoma.
Objective:
To see if marizomib stops tumor growth and prlongs the time that the tumor is controlled.
Eligibility:
Adults age 18 and older who have been diagnosed with ependymomas and have already been
treated with standard therapies
Design:
Participants will be screened with the following tests or recent results from similar tests:
- Medical history
- Physical exam
- Neurological assessment
- Electrocardiogram (EKG) to evaluate the heart
- Review of symptoms and ability to perform normal activities
- Computed tomographic scan (CT) or magnetic resonance imaging (MRI) to produce an image
of the brain or spine.
- Blood and urine tests
- Tests of tumor samples. Participants may have to have new tumor samples taken.
Participants will get the study drug in cycles. Each cycle is 4 weeks. Participants will have
up to 24 cycles.
Participants will get the study drug through a small plastic tube in a vein on days 1, 8, and
15 of each cycle.
During each cycle, some screening tests will be repeated.
Participants will answer questions about their general well-being and functioning.
About 4 5 weeks after finishing the study drug, participants will have a follow-up visit.
They will answer questions about their health, get a physical and a neurological exam, and
have blood tests. They may have an MRI or CT scan.
...